Skip to content

Doctors and patients are flying blind as medical marijuana use rises, research lags

July 25, 2019 / Arfinn Med MD /

Doctors and patients are flying blind as medical marijuana use rises, research lags

Marijuana’s role in the health care universe has grown exponentially over the past few years. Currently, 33 U.S. states have legalized the use of medical marijuana, and more and more states are considering making it legal for recreational purposes as well. As cannabis becomes more accessible, many people are turning to tetrahydrocannabinol (THC) and cannabidiol (CBD) products to treat health issues like rheumatic and musculoskeletal disease (the aches and pains of arthritis).

Unfortunately, because cannabis remains illegal and classified as a Schedule 1 drugunder federal law (defined as being of no medical use), there has been a troubling lack of scientific and medical research on the effectiveness of cannabis treatments. This dearth of evidence-based data has left many health care providers unable to counsel their patients on everything from whether a cannabis treatment could be effective for their condition, to what dosages are appropriate, to how cannabis might interact with their other medications or health conditions.

Read Full Article Here

Stories you may be interested in

New study finds cannabis effective for treating migraines

A study published last month in the Journal of Pain found a statistically significant reduction in migraine and headache symptoms and recurrences among patients who used cannabis for treatment.Smoking cannabis reduced the severity and length of migraine episodes by nearly half. Researchers concluded that headache and migraine severity were reduced by nearly 50% after using cannabis. The study, conducted by researchers…
Read More →

Older adults and medical marijuana: Reduced stigma and increased use

As a primary care doctor who has incorporated medical cannabis into his practice, it is notable how many silver-haired patients are coming in to discuss the pros and cons of a trial of medical cannabis. These patients range from people in their 60s with kidney failure who can no longer take certain pain medications but…
Read More →

REGISTRATION NOW OPEN: Arfinn Med Medical Cannabis Efficacy Portal for Licensed Medical Professionals

Arfinn Med, the first clinician-based medical professional and patient efficacy portal for medical cannabis treatments, is now open for registrations from licensed medical professionals. The free collaborative portal allows medical professionals to register, share, research and communicate HIPAA-compliant benchmark data for medical cannabis treatments. As a free tool for physicians, Arfinn Med offers a new…
Read More →

Norfolk research company plans clinical trials using medical marijuana

Eighteen months after receiving a broad federal license for importing medical cannabis, a Norfolk research company is about to embark on a series of critical studies into a variety of medical and mental disorders, diseases and conditions. Sanyal Biotechnology is already considering proposals for research campuses and planning its first clinical trial for this summer.…
Read More →

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More →

Cannabis and Seniors

As more and more research comes out regarding the medical benefits of cannabis, it’s important to keep up with new research as it becomes available.  Here at Arfinn Med, we constantly review new studies and look at our own deidentified efficacy data to try to find any additional insights we can relay to our registered…
Read More →

Leave a Comment

You must be logged in to post a comment.